Compare Stocks: TARA, OLMA, DSGN, and WVE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSGN Design Therapeutics	$12.24 -2.6%	$13.85	$5.28 ▼ $17.25	$786.65M	1.68	729,986 shs	346,590 shs
OLMA Olema Pharmaceuticals	$8.27 -4.3%	$10.51	$6.65 ▼ $36.26	$755.98M	2	1.23 million shs	1.01 million shs
TARA Protara Therapeutics	$2.76 -9.5%	$3.80	$2.74 ▼ $7.82	$180.24M	1.47	1.29 million shs	5.00 million shs
WVE WAVE Life Sciences	$3.88 +4.9%	$4.99	$3.56 ▼ $21.73	$729.08M	-1.42	3.13 million shs	5.41 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSGN Design Therapeutics	-2.63%	0.00%	-19.15%	-21.74%	+80.27%
OLMA Olema Pharmaceuticals	-4.28%	-8.52%	-21.69%	-34.57%	-25.09%
TARA Protara Therapeutics	-9.51%	-17.61%	-29.23%	-32.02%	-37.41%
WVE WAVE Life Sciences	+4.86%	-2.02%	-21.93%	-38.02%	-44.81%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSGN Design Therapeutics	$12.24 -2.6%	$13.85	$5.28 ▼ $17.25	$786.65M	1.68	729,986 shs	346,590 shs
OLMA Olema Pharmaceuticals	$8.27 -4.3%	$10.51	$6.65 ▼ $36.26	$755.98M	2	1.23 million shs	1.01 million shs
TARA Protara Therapeutics	$2.76 -9.5%	$3.80	$2.74 ▼ $7.82	$180.24M	1.47	1.29 million shs	5.00 million shs
WVE WAVE Life Sciences	$3.88 +4.9%	$4.99	$3.56 ▼ $21.73	$729.08M	-1.42	3.13 million shs	5.41 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSGN Design Therapeutics	-2.63%	0.00%	-19.15%	-21.74%	+80.27%
OLMA Olema Pharmaceuticals	-4.28%	-8.52%	-21.69%	-34.57%	-25.09%
TARA Protara Therapeutics	-9.51%	-17.61%	-29.23%	-32.02%	-37.41%
WVE WAVE Life Sciences	+4.86%	-2.02%	-21.93%	-38.02%	-44.81%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	34.80% Upside
OLMA Olema Pharmaceuticals	2.77	Moderate Buy	$40.60	390.93% Upside
TARA Protara Therapeutics	2.75	Moderate Buy	$26.25	851.09% Upside
WVE WAVE Life Sciences	2.78	Moderate Buy	$21.59	456.40% Upside

Current Analyst Ratings Breakdown

Latest TARA, OLMA, DSGN, and WVE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/1/2026	WVE WAVE Life Sciences	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
9/23/2026	WVE WAVE Life Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight ➝ Neutral
9/21/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/14/2026	OLMA Olema Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$48.00 ➝ $30.00
8/31/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/19/2026	WVE WAVE Life Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$52.00 ➝ $46.00
8/11/2026	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$38.00 ➝ $36.00
8/11/2026	OLMA Olema Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$59.00
8/4/2026	WVE WAVE Life Sciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$27.00 ➝ $23.00

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.73 per share	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.88 per share	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$3.80 per share	N/A
WVE WAVE Life Sciences	$42.73M	17.89	N/A	N/A	$3.10 per share	1.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
OLMA Olema Pharmaceuticals	-$162.45M	-$2.12	N/A	N/A	N/A	N/A	-48.26%	-43.04%	11/9/2026 (Estimated)
TARA Protara Therapeutics	-$57.44M	-$1.35	N/A	N/A	N/A	N/A	-41.72%	-38.78%	11/9/2026 (Estimated)
WVE WAVE Life Sciences	-$204.38M	-$1.09	N/A	N/A	N/A	-309.73%	-50.36%	-40.06%	11/9/2026 (Estimated)

Latest TARA, OLMA, DSGN, and WVE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	TARA Protara Therapeutics	-$0.3257	-$0.36	-$0.0343	-$0.36	N/A	N/A
8/10/2026	Q2 2026	OLMA Olema Pharmaceuticals	-$0.5515	-$0.61	-$0.0585	-$0.61	N/A	N/A
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A
7/30/2026	Q2 2026	WVE WAVE Life Sciences	-$0.2998	-$0.34	-$0.0403	-$0.34	$7.45 million	$2.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSGN Design Therapeutics	N/A	18.86	18.86
OLMA Olema Pharmaceuticals	0.01	8.86	8.86
TARA Protara Therapeutics	N/A	10.97	10.97
WVE WAVE Life Sciences	N/A	9.99	9.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSGN Design Therapeutics	56.64%
OLMA Olema Pharmaceuticals	91.78%
TARA Protara Therapeutics	38.13%
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
DSGN Design Therapeutics	17.10%
OLMA Olema Pharmaceuticals	12.56%
TARA Protara Therapeutics	7.60%
WVE WAVE Life Sciences	24.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSGN Design Therapeutics	55	62.58 million	51.88 million	Optionable
OLMA Olema Pharmaceuticals	150	87.50 million	76.51 million	Optionable
TARA Protara Therapeutics	51	59.10 million	54.60 million	Optionable
WVE WAVE Life Sciences	317	197.05 million	149.17 million	Optionable

TARA, OLMA, DSGN, and WVE Headlines

Recent News About These Companies

Wave Life Sciences gets FDA backing for WVE-006 registrational trial

October 1 at 5:50 PM | streetinsider.com

Wave Life Sciences Says FDA Feedback Supports Registrational Pathway for WVE-006

October 1 at 12:49 PM | finance.yahoo.com

Wave Gains FDA Support For WVE-006 Registrational Pathway In AATD

October 1 at 12:49 PM | rttnews.com

Wave Life Sciences Says FDA Feedback Supports Genetic Disease Treatment

October 1 at 12:49 PM | marketwatch.com

Wave Life jumps as FDA backs registrational plans for AATD therapy

October 1 at 12:49 PM | seekingalpha.com

WAVE Life Sciences (NASDAQ:WVE) Shares Up 9.3% - Here's Why

October 1 at 12:39 PM | marketbeat.com

LADENBURG THALM/SH SH Initiates Coverage on WAVE Life Sciences (NASDAQ:WVE)

October 1 at 9:05 AM | marketbeat.com

Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD

October 1 at 7:30 AM | globenewswire.com

Wave Life Sciences Earns $12 Million Milestone as GSK Advances Liver Drug

September 30 at 11:47 AM | marketscreener.comM

Wave Life Science Advance Liver-Focused SiRNA Program With GSK; Stock Up

September 30 at 11:47 AM | rttnews.com

WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up - Here's Why

September 30 at 11:19 AM | marketbeat.com

Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development

September 30 at 7:30 AM | globenewswire.com

Wave Life Sciences Ltd (WVE)

September 29 at 11:06 PM | uk.investing.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 29 at 2:13 AM | marketbeat.com

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation

September 28, 2026 | zacks.com

WAVE Life Sciences (NASDAQ:WVE) Hits New 52-Week Low - Should You Sell?

September 28, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM) and Wave Life Sciences (WVE)

September 25, 2026 | theglobeandmail.com

WAVE Life Sciences (NASDAQ:WVE) Stock Picked Up by Analysts at JPMorgan Chase & Co.

September 25, 2026 | americanbankingnews.com

Wave Life Sciences Ltd. lance un essai combiné de phase 2a de WVE-007 avec le tirzépatide dans l’obésité

September 24, 2026 | zonebourse.comZ

Wave Life Sciences Ltd. Initiates Phase 2A Combination Trial of Wve-007 with Tirzepatide for Obesity

September 24, 2026 | marketscreener.comM

JP Morgan Downgrades Wave Life Sciences to Neutral from Overweight

September 24, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA, OLMA, DSGN, and WVE Company Descriptions

Design Therapeutics NASDAQ:DSGN

$12.24 -0.33 (-2.63%)

Closing price 10/1/2026 04:00 PM Eastern

Extended Trading

$12.78 +0.54 (+4.40%)

As of 07:12 AM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Olema Pharmaceuticals NASDAQ:OLMA

$8.27 -0.37 (-4.28%)

Closing price 10/1/2026 04:00 PM Eastern

Extended Trading

$8.39 +0.12 (+1.46%)

As of 07:21 AM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Protara Therapeutics NASDAQ:TARA

$2.76 -0.29 (-9.51%)

Closing price 10/1/2026 04:00 PM Eastern

Extended Trading

$2.80 +0.04 (+1.41%)

As of 07:10 AM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

WAVE Life Sciences NASDAQ:WVE

$3.88 +0.18 (+4.86%)

Closing price 10/1/2026 04:00 PM Eastern

Extended Trading

$3.85 -0.03 (-0.67%)

As of 07:01 AM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TARA, OLMA, DSGN, and WVE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TARA, OLMA, DSGN, and WVE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TARA, OLMA, DSGN, and WVE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA, OLMA, DSGN, and WVE Company Descriptions

Design Therapeutics NASDAQ:DSGN

Olema Pharmaceuticals NASDAQ:OLMA

Protara Therapeutics NASDAQ:TARA

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TARA, OLMA, DSGN, and WVE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TARA, OLMA, DSGN, and WVE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TARA, OLMA, DSGN, and WVE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA, OLMA, DSGN, and WVE Company Descriptions

Design Therapeutics NASDAQ:DSGN

Olema Pharmaceuticals NASDAQ:OLMA

Protara Therapeutics NASDAQ:TARA

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools